drugset / Trial / NCT02655315

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

NCT02655315

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.

Timeline

Start
2016-02-09
Primary completion
2020-09-22
Completion
2020-09-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Deferiprone Small molecule 15 mg/kg Oral

Indications